Characterization of a surrogate murine antibody to model anti-human CD3 therapies

Por Dépis, Fabien, Hatterer, Eric, Ballet, Romain, Daubeuf, Bruno, Cons, Laura, Glatt, Sophie, Reith, Walter, Kosco-Vilbois, Marie, Dean, Yann
Publicado em 2013

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

Por Glatt, Sophie, Helmer, Eric, Haier, Birgit, Strimenopoulou, Foteini, Price, Graham, Vajjah, Pavan, Harari, Olivier A., Lambert, John, Shaw, Stevan
Publicado no Br J Clin Pharmacol (2017)

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F co...

Por Glatt, Sophie, Baeten, Dominique, Baker, Terry, Griffiths, Meryn, Ionescu, Lucian, Lawson, Alastair D G, Maroof, Ash, Oliver, Ruth, Popa, Serghei, Strimenopoulou, Foteini, Vajjah, Pavan, Watling, Mark I L, Yeremenko, Nataliya, Miossec, Pierre, Shaw, Stevan
Publicado no Ann Rheum Dis (2018)